NO20052814L - Cytomodulerende peptider for behandling av interstitielle cystitt - Google Patents

Cytomodulerende peptider for behandling av interstitielle cystitt

Info

Publication number
NO20052814L
NO20052814L NO20052814A NO20052814A NO20052814L NO 20052814 L NO20052814 L NO 20052814L NO 20052814 A NO20052814 A NO 20052814A NO 20052814 A NO20052814 A NO 20052814A NO 20052814 L NO20052814 L NO 20052814L
Authority
NO
Norway
Prior art keywords
treatment
interstitial cystitis
cytomodulatory
peptides
modulation
Prior art date
Application number
NO20052814A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052814D0 (no
Inventor
Alexis E Te
Timothy Fong
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of NO20052814D0 publication Critical patent/NO20052814D0/no
Publication of NO20052814L publication Critical patent/NO20052814L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20052814A 2002-11-15 2005-06-10 Cytomodulerende peptider for behandling av interstitielle cystitt NO20052814L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42668402P 2002-11-15 2002-11-15
US47083903P 2003-05-15 2003-05-15
PCT/US2003/037043 WO2004045554A2 (fr) 2002-11-15 2003-11-17 Peptides de cytomodulation permettant de traiter la cystite interstitielle

Publications (2)

Publication Number Publication Date
NO20052814D0 NO20052814D0 (no) 2005-06-10
NO20052814L true NO20052814L (no) 2005-08-04

Family

ID=32329122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052814A NO20052814L (no) 2002-11-15 2005-06-10 Cytomodulerende peptider for behandling av interstitielle cystitt

Country Status (13)

Country Link
US (1) US7671026B2 (fr)
EP (1) EP1594519A4 (fr)
JP (1) JP2006516546A (fr)
KR (1) KR20050086676A (fr)
AU (1) AU2003294357A1 (fr)
BR (1) BR0316290A (fr)
CA (1) CA2505922A1 (fr)
CO (1) CO5640064A2 (fr)
MA (1) MA27607A1 (fr)
MX (1) MXPA05005101A (fr)
NO (1) NO20052814L (fr)
RU (1) RU2005118425A (fr)
WO (1) WO2004045554A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE543097T1 (de) * 2006-07-27 2012-02-15 Univ Maryland Zellulärer rezeptor für antiproliferativen faktor
DK2252627T3 (en) * 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
CA2734325A1 (fr) * 2008-08-18 2010-02-25 University Of Maryland, Baltimore Derives d'apf et methodes d'utilisation afferentes
WO2012048721A1 (fr) 2010-10-14 2012-04-19 Xigen S.A. Utilisation d'inhibiteurs peptidiques, aptes à pénétrer dans les cellules, de la voie de transduction du signal jnk pour le traitement de maladies oculaires inflammatoires chroniques ou non-chroniques
EP3010939A2 (fr) 2013-06-17 2016-04-27 Asana BioSciences, LLC Molécule d'immunofusion ciblant 5t4 et procédés correspondants
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2014206426A1 (fr) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation des molécules inhibitrices de la jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
EP3160489B9 (fr) * 2014-06-26 2023-10-04 Xigen Inflammation Ltd. Inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de la cystite
US10859579B2 (en) * 2016-03-31 2020-12-08 William Beaumont Hospital Methods for detecting, diagnosing and treating ulcerative interstitial cystitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500287A (en) * 1997-04-11 2002-10-25 Sangstat Medical Corp Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
CA2328774A1 (fr) * 1998-04-17 1999-10-28 John Warren Procede servant a traiter la cystite interstitielle au moyen d'un facteur de croissance semblable au facteur de croissance epidermique de recombinaison se fixant a heparine (hb-egf)
KR20050057175A (ko) * 2002-09-20 2005-06-16 알콘, 인코퍼레이티드 안구건조증 치료용 사이토카인 합성 저해제의 용도

Also Published As

Publication number Publication date
RU2005118425A (ru) 2006-02-10
MA27607A1 (fr) 2005-11-01
WO2004045554A2 (fr) 2004-06-03
US7671026B2 (en) 2010-03-02
WO2004045554A3 (fr) 2005-07-07
US20060194738A1 (en) 2006-08-31
NO20052814D0 (no) 2005-06-10
EP1594519A2 (fr) 2005-11-16
JP2006516546A (ja) 2006-07-06
AU2003294357A1 (en) 2004-06-15
CA2505922A1 (fr) 2004-06-03
CO5640064A2 (es) 2006-05-31
BR0316290A (pt) 2005-10-11
KR20050086676A (ko) 2005-08-30
EP1594519A4 (fr) 2006-08-16
MXPA05005101A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
NO20052814L (no) Cytomodulerende peptider for behandling av interstitielle cystitt
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO20053041L (no) Behandling av diabetes.
MY140767A (en) Compounds, methods and compositions
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
PL374865A1 (en) Treatment of tnf alpha related disorders
WO2001062272A3 (fr) Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
WO2005027993A3 (fr) Preservation d'acces vasculaire chez des patients en hemodialyse
AU2003238023A1 (en) Method of evaluating myelosuppressive state
WO2006130679A3 (fr) Composition et methode de traitement de rhinite allergique
NO20052267L (no) Forbindelser, Preparater og Metoder